Gencurix Inc

Gencurix Inc has a market capitalization of KRW 45,153,062,850 and a price-to-book ratio of 4.26, indicating that the market values the company at a premium to its book value. The company's liquidity position is weak, with a current ratio of 0.22, suggesting that it has insufficient current assets to cover its current liabilities. Additionally, the company has a negative net cash position after subtracting total debt, which raises concerns about its short-term liquidity.

The company's profitability is severely underperforming, with a return on equity (ROE) of -0.3825 and a return on assets (ROA) of -0.1693, both of which are significantly below the industry median for medical equipment and supplies firms. The operating loss of KRW -2,780,825,100 and net loss of KRW -4,054,103,580 further underscore the company's financial distress. The company's debt-to-equity ratio of 0.9 indicates a moderate level of leverage, but the negative operating cash flow of KRW -4,148,683,150 and free cash flow of KRW -3,788,617,970 suggest that it is not generating sufficient cash to service its debt obligations.

Gencurix's revenue of KRW 562,889,490 is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another. The company's capital expenditures of KRW -378,698,620 indicate ongoing investment in its operations, but the negative free cash flow suggests that these investments are not yet generating returns.

The company's growth trajectory is negative, with a net loss of KRW -4,054,103,580 in the latest reporting period. The outlook for the current fiscal year is not provided, but the company's financial performance suggests that it is unlikely to achieve significant revenue growth in the near term. The company's operating cash flow and free cash flow are both negative, indicating that it is not generating sufficient cash to fund its operations or support growth initiatives.

The company's risk profile is elevated, with a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could lead to liquidity constraints and the need for additional financing. The company's debt-to-equity ratio of 0.9 suggests that it is not overly leveraged, but the negative operating cash flow and free cash flow indicate that it is not generating sufficient cash to service its debt obligations. The company's dilution risk is low, but the potential for future dilution remains a concern if the company needs to raise additional capital to fund its operations.

Recent events, including the company's financial performance and capital structure, suggest that it is facing significant challenges. The company's operating loss and net loss indicate that it is not currently profitable, and the negative cash flows suggest that it is not generating sufficient cash to fund its operations. The company's capital expenditures indicate ongoing investment in its operations, but the negative free cash flow suggests that these investments are not yet generating returns. The company's financial performance and capital structure suggest that it may need to seek additional financing to support its operations and growth initiatives.

Revenue grew 47% year-over-year to 7.5 billion KRW, demonstrating strong top-line expansion momentum.

The company achieved a 25.5% revenue CAGR over four years, indicating consistent long-term growth trajectory.

Cash conversion ratio of 1.02 exceeds the cohort median of 0.84, suggesting efficient cash management.

Long-term debt decreased significantly from 9.9 billion KRW to 615 million KRW, reducing leverage risk.

Dilution risk is assessed as low, providing some protection for existing shareholder equity value.

Operating and net margins rank in the bottom quartile of the medical equipment cohort.

The company faces high credit risk and medium liquidity risk, threatening financial stability.